Astellas’ Potential Zelnorm Competitor Ramosetron Poised For Phase III Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Astellas Pharmaceuticals could enter U.S. Phase III studies with its diarrhea-predominant irritable bowel syndrome agent YM060 (ramosetron) as soon as the first half of 2008, Executive VP Toshinari Tamura told analysts during a third quarter earnings call Feb. 1